metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus capecitabine, placebo plus bevacizumab
	atezolizumab plus bevacizumab
	BACCI, 2022 JAMA Netw Open 2022; 5:e2149040-. NCT02873195	RCT	mCRC - 2nd line (L2)	capecitabine plus bevacizumab plus atezolizumab	capecitabine plus bevacizumab plus placebo	Patients 18 years and older with Refractory Metastatic Colorectal Cancer	82 / 46	low	inconclusive	inconclusive 27 % decrease in progression or deaths (PFS) (PE) In this randomized clinical trial, the addition of atezolizumab to capecitabine and bevacizumab therapy provided limited (ie, not clinically meaningful) clinical benefit. Patients with MSS and proficient mismatch repair tumors and those without liver metastasis benefited more
versus regorafenib
	atezolizumab alone
	IMblaze-370 (A ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab monotherapy	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	90 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)
	atezolizumab plus cometinib
	IMblaze-370 (AC ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab plus cometinib	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer with disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	183 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)